FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020139819> ?p ?o ?g. }

• W2020139819 endingPage "e95681" @default.
• W2020139819 startingPage "e95681" @default.
• W2020139819 abstract "Background Recent multi-centre trials showed that dihydroartemisinin-piperaquine (DP) was as efficacious and safe as artemether-lumefantrine (AL) for treatment of young children with uncomplicated P. falciparum malaria across diverse transmission settings in Africa. Longitudinal follow-up of patients in these trials supported previous findings that DP had a longer post-treatment prophylactic effect than AL, reducing the risk of reinfection and conferring additional health benefits to patients, particularly in areas with moderate to high malaria transmission. Methods We developed a Markov model to assess the cost-effectiveness of DP versus AL for first-line treatment of uncomplicated malaria in young children from the provider perspective, taking into consideration the post-treatment prophylactic effects of the drugs as reported by a recent multi-centre trial in Africa and using the maximum manufacturer drug prices for artemisinin-based combination therapies set by the Global Fund in 2013. We estimated the price per course of treatment threshold above which DP would cease to be a cost-saving alternative to AL as a first-line antimalarial drug. Results First-line treatment with DP compared to AL averted 0.03 DALYs (95% CI: 0.006–0.07) and 0.001 deaths (95% CI: 0.00–0.002) and saved $0.96 (95% CI: 0.33–2.46) per child over one year. The results of the threshold analysis showed that DP remained cost-saving over AL for any DP cost below $1.23 per course of treatment. Conclusions DP is superior to AL from both the clinical and economic perspectives for treatment of uncomplicated P. falciparum malaria in young children. A paediatric dispersible formulation of DP is under development and should facilitate a targeted deployment of this antimalarial drug. The use of DP as first-line antimalarial drug in paediatric malaria patients in moderate to high transmission areas of Africa merits serious consideration by health policymakers." @default.
• W2020139819 created "2016-06-24" @default.
• W2020139819 creator A5036346559 @default.
• W2020139819 creator A5042818572 @default.
• W2020139819 creator A5090639293 @default.
• W2020139819 date "2014-04-18" @default.
• W2020139819 modified "2023-10-14" @default.
• W2020139819 title "Dihydroartemisinin-Piperaquine vs. Artemether-Lumefantrine for First-Line Treatment of Uncomplicated Malaria in African Children: A Cost-Effectiveness Analysis" @default.
• W2020139819 cites W1275343739 @default.
• W2020139819 cites W1817283835 @default.
• W2020139819 cites W2000992267 @default.
• W2020139819 cites W2027553151 @default.
• W2020139819 cites W2031911156 @default.
• W2020139819 cites W2036368368 @default.
• W2020139819 cites W2097782152 @default.
• W2020139819 cites W2110383454 @default.
• W2020139819 cites W2113913859 @default.
• W2020139819 cites W2116510803 @default.
• W2020139819 cites W2121293261 @default.
• W2020139819 cites W2122664355 @default.
• W2020139819 cites W2122967261 @default.
• W2020139819 cites W2123388015 @default.
• W2020139819 cites W2128743785 @default.
• W2020139819 cites W2142060065 @default.
• W2020139819 cites W2156469502 @default.
• W2020139819 cites W2156984950 @default.
• W2020139819 cites W2157656397 @default.
• W2020139819 cites W2163995382 @default.
• W2020139819 cites W2164861997 @default.
• W2020139819 cites W2168604498 @default.
• W2020139819 doi "https://doi.org/10.1371/journal.pone.0095681" @default.
• W2020139819 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3991722" @default.
• W2020139819 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24748395" @default.
• W2020139819 hasPublicationYear "2014" @default.
• W2020139819 type Work @default.
• W2020139819 sameAs 2020139819 @default.
• W2020139819 citedByCount "18" @default.
• W2020139819 countsByYear W20201398192014 @default.
• W2020139819 countsByYear W20201398192015 @default.
• W2020139819 countsByYear W20201398192016 @default.
• W2020139819 countsByYear W20201398192017 @default.
• W2020139819 countsByYear W20201398192018 @default.
• W2020139819 countsByYear W20201398192019 @default.
• W2020139819 countsByYear W20201398192020 @default.
• W2020139819 countsByYear W20201398192022 @default.
• W2020139819 countsByYear W20201398192023 @default.
• W2020139819 crossrefType "journal-article" @default.
• W2020139819 hasAuthorship W2020139819A5036346559 @default.
• W2020139819 hasAuthorship W2020139819A5042818572 @default.
• W2020139819 hasAuthorship W2020139819A5090639293 @default.
• W2020139819 hasBestOaLocation W20201398191 @default.
• W2020139819 hasConcept C112930515 @default.
• W2020139819 hasConcept C126322002 @default.
• W2020139819 hasConcept C203014093 @default.
• W2020139819 hasConcept C2776120307 @default.
• W2020139819 hasConcept C2777616469 @default.
• W2020139819 hasConcept C2778048844 @default.
• W2020139819 hasConcept C2778118209 @default.
• W2020139819 hasConcept C2778371730 @default.
• W2020139819 hasConcept C2778629330 @default.
• W2020139819 hasConcept C2780780316 @default.
• W2020139819 hasConcept C2781160685 @default.
• W2020139819 hasConcept C3019080777 @default.
• W2020139819 hasConcept C515549039 @default.
• W2020139819 hasConcept C535046627 @default.
• W2020139819 hasConcept C71924100 @default.
• W2020139819 hasConceptScore W2020139819C112930515 @default.
• W2020139819 hasConceptScore W2020139819C126322002 @default.
• W2020139819 hasConceptScore W2020139819C203014093 @default.
• W2020139819 hasConceptScore W2020139819C2776120307 @default.
• W2020139819 hasConceptScore W2020139819C2777616469 @default.
• W2020139819 hasConceptScore W2020139819C2778048844 @default.
• W2020139819 hasConceptScore W2020139819C2778118209 @default.
• W2020139819 hasConceptScore W2020139819C2778371730 @default.
• W2020139819 hasConceptScore W2020139819C2778629330 @default.
• W2020139819 hasConceptScore W2020139819C2780780316 @default.
• W2020139819 hasConceptScore W2020139819C2781160685 @default.
• W2020139819 hasConceptScore W2020139819C3019080777 @default.
• W2020139819 hasConceptScore W2020139819C515549039 @default.
• W2020139819 hasConceptScore W2020139819C535046627 @default.
• W2020139819 hasConceptScore W2020139819C71924100 @default.
• W2020139819 hasIssue "4" @default.
• W2020139819 hasLocation W20201398191 @default.
• W2020139819 hasLocation W20201398192 @default.
• W2020139819 hasLocation W20201398193 @default.
• W2020139819 hasLocation W20201398194 @default.
• W2020139819 hasLocation W20201398195 @default.
• W2020139819 hasOpenAccess W2020139819 @default.
• W2020139819 hasPrimaryLocation W20201398191 @default.
• W2020139819 hasRelatedWork W1571339142 @default.
• W2020139819 hasRelatedWork W1822671023 @default.
• W2020139819 hasRelatedWork W2020139819 @default.
• W2020139819 hasRelatedWork W2077188081 @default.
• W2020139819 hasRelatedWork W2147526348 @default.
• W2020139819 hasRelatedWork W2960101348 @default.
• W2020139819 hasRelatedWork W2995187875 @default.
• W2020139819 hasRelatedWork W4210932539 @default.
• W2020139819 hasRelatedWork W4293447100 @default.

• next